Results 211 to 220 of about 6,906,309 (313)

Walking in Balance: A Sicangu Lakota Message to the Ecological Society of America

open access: yes
The Bulletin of the Ecological Society of America, EarlyView.
Phil Two Eagle
wiley   +1 more source

C‐Terminal Tail Elongation Adds a New Dimension to the Tubulin Code

open access: yesCytoskeleton, EarlyView.
ABSTRACT Tubulin C‐terminal tails undergo diverse post‐translational modifications that regulate microtubule interactions with motors and severing enzymes. TTLL11, a member of the tubulin tyrosine ligase‐like (TTLL) family, uniquely catalyzes glutamate addition to the terminal α‐carboxyl group of both α‐ and β‐primary tubulin tails.
Jana Campbell, Cyril Barinka
wiley   +1 more source

Prenatal melamine, aromatic amine, and psychosocial stress exposures and their association with gestational diabetes mellitus in a San Francisco pregnancy cohort. [PDF]

open access: yesJ Expo Sci Environ Epidemiol
Lasher E   +7 more
europepmc   +1 more source

Fetal Pain Perception: Legislative Assertions and Developmental Neuroscience

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Background Pain perception is a conscious experience, but neither pain nor consciousness is defined in the developing human fetus. Emergent consciousness may be regarded as a phenomenon that ultimately arises from an essential minimum of functional neuronal connectivity. Proposed U.S.
William D. Graf   +9 more
wiley   +1 more source

An Update to the Clinical Pharmacogenetics Implementation Consortium (CPIC) SLCO1B1 Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub‐Saharan African Ancestry

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has formally updated the SLCO1B1 allele functionality table based on new evidence. Notably, the alleles studied (SLCO1B1 *9, *31, *41) are enriched in the genomes of patients historically excluded from pharmacogenomics research.
Akinyemi Oni‐Orisan   +6 more
wiley   +1 more source

An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The FDA published guidance on assessing pharmacokinetics (PK) in participants with impaired renal function in 2024. The IQ CPLG Organ Impairment Working Group summarized the industry’s perspective on this guidance by highlighting a few key updates in the 2024 guidance, including: (1) the recommendation of using estimated glomerular filtration rate ...
Yan Jin   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy